Ozempic maker Novo Nordisk downgraded to sell after 70% stock-price dive from peak

Deutsche Bank’s decision to downgrade Novo Nordisk to “sell” marks a notable shift in Wall Street sentiment. Until Thursday, analysts had largely refrained from advising investors to exit the Danish pharmaceutical giant, even after its shares tumbled roughly 70% from their peak. The downgrade signals that the post-pandemic enthusiasm for GLP-1 weight-loss drugs, which once made Novo one of Europe’s most valuable companies, has cooled significantly.

For context, the stock’s decline reflects a combination of factors, including intensifying competition in the obesity-treatment market, pricing pressures, and concerns about the sustainability of demand. Deutsche Bank’s move adds a formal bearish voice to what had been a mostly cautious-but-hold consensus. For market participants, the downgrade matters because it may prompt other banks to reassess their own ratings, potentially amplifying selling pressure.

What to watch now: upcoming clinical trial data, regulatory decisions, and quarterly earnings commentary will be key in determining whether Novo’s outlook stabilizes or deteriorates further. Investors should also monitor how peers in the GLP-1 space respond, as competitive dynamics will likely dictate the sector’s direction.